How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
HPV Reagent Market
- By Product Type: DNA Probes, PCR Reagents, Enzymes, Buffers and Solutions, Controls and Standards
- By Application: HPV Genotyping, HPV Detection, HPV Viral Load Quantification, HPV Vaccine Development, Research and Development
- By End User: Clinical Diagnostic Laboratories, Research Laboratories, Hospitals and Clinics, Biotechnology Companies, Academic and Government Research Institutes
- By Technology: Real-Time PCR, Hybridization Assays, Next-Generation Sequencing, Microarray Technology, Isothermal Amplification
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - DNA Probes leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the HPV Reagent Market report
A complete, evidence-based study - 11 chapters and 119 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
Application 5
End User 5
Technology 5
Companies profiled
Roche Diagnostics
Qiagen
Hologic Inc.
Abbott Laboratories
Becton
Dickinson and Company (BD)
Thermo Fisher Scientific
PerkinElmer Inc.
F. Hoffmann-La Roche AG
Siemens Healthineers
Genomica S.A.U.
Sekisui Diagnostics
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Roche Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Qiagen
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Hologic Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Becton
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Dickinson and Company (BD)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →PerkinElmer Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →F. Hoffmann-La Roche AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Siemens Healthineers
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Genomica S.A.U.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Sekisui Diagnostics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Biorad Laboratories
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Cepheid
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Myriad Genetics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Nanjing Vazyme Biotech Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$9,768M by 2033 · 11.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- DNA Probes40.1
- PCR Reagents10.7
- Enzymes13.2
- Buffers and Solutions16.7
- Controls and Standards19.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,397M → $3,338M · 11.5%
Europe$973.7M → $2,363M · 11.7%
Asia Pacific$889.0M → $2,178M · 11.9%
Latin America$550.3M → $1,147M · 9.6%
Middle East and Africa$423.3M → $975.1M · 11.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.972026
10.972027
10.992028
11.002029
11.022030
11.032031
11.032032
11.062033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Roche Diagnostics25.4
- Qiagen12.1
- Hologic Inc.7.5
- Abbott Laboratories7.9
- Becton7.4
- Dickinson and Company (BD)11.7
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type15.1%
Application22.7%
End User29.4%
Technology32.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.4
- Europe23.6
- Asia Pacific21.8
- Latin America11.5
- Middle East and Africa9.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Roche Diagnostics | 77 | 74 | 94 | 74 | 80 | 99 | 83 |
| Qiagen | 89 | 82 | 83 | 81 | 80 | 78 | 82 |
| Hologic Inc. | 72 | 67 | 64 | 88 | 72 | 75 | 73 |
| Abbott Laboratories | 61 | 68 | 74 | 71 | 69 | 79 | 70 |
| Becton | 72 | 55 | 53 | 74 | 70 | 73 | 66 |
| Dickinson and Company (BD) | 59 | 56 | 61 | 69 | 62 | 59 | 61 |
| Thermo Fisher Scientific | 54 | 52 | 49 | 51 | 43 | 53 | 50 |
| PerkinElmer Inc. | 46 | 47 | 43 | 49 | 52 | 46 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Roche Diagnostics
- Qiagen
- Hologic Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Roche Diagnostics | ✓ | ◐ | ◐ | ✓ | ◐ | ✓ |
| Qiagen | ✓ | ✓ | ◐ | ✓ | ✓ | ◐ |
| Hologic Inc. | ◐ | ◐ | ◐ | ◐ | ✓ | ◐ |
| Abbott Laboratories | − | − | ✓ | ◐ | − | ✓ |
| Becton | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Dickinson and Company (BD) | − | ◐ | − | ◐ | ◐ | − |
| Thermo Fisher Scientific | ◐ | − | − | − | − | − |
| PerkinElmer Inc. | − | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Roche Diagnostics83
2Qiagen82
3Hologic Inc.73
4Abbott Laboratories70
5Becton66
6Dickinson and Company (BD)61
7Thermo Fisher Scientific50
8PerkinElmer Inc.47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Roche DiagnosticsQiagen
Challenger2
Strong scale, closing on the leaders.
Hologic Inc.Abbott Laboratories
Contender2
Focused players with pockets of strength.
BectonDickinson and Company (BD)
Niche2
Specialists in a single segment or region.
Thermo Fisher ScientificPerkinElmer Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Type in North America, then scale across HPV Reagent Market — a $701M beachhead inside a $11.8B market.
Beachhead (SOM)$701Mobtainable near-term
Serviceable (SAM)$4.79Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
DNA Probes
Best fit — highest urgency & budget in Product Type.
Economic buyer77 fit
PCR Reagents
Strong fit — clear ROI and a fast path to value.
End user66 fit
Enzymes
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel28%
Digital / self-serve22%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win HPV Reagent Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified22%
Evaluation12%
Closed-won6%
$12.1KCAC
$47KLTV
3.9:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
HPV Reagent Market is a high-growth opportunity — $5.60B by 2033, compounding at 11.2%.
TAM · 2025$2.40Btoday
TAM · 2033$5.60Bforecast
CAGR11.2%2027–2033
Cumulative$34.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.60BTotal addressable market
SAM$1.94BServiceable available market
SOM$392MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.2% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.60BLarge & growingTAM by 2033 at 11.2% CAGR
$1.94BServiceable nowreachable with today’s model
$392MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.37BBear7.3% CAGR
$5.60BBase11.2% CAGR
$7.17BBull14.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
HPV Reagent Market — a $11.0B market by 2033. Plan: grow share from 9.0% to 18.9%.
Market size · 2033$11.0Btotal addressable
Market CAGR11.4%2027–2033
Target share18.9%from 9.0% today
Revenue ambition$2.08Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.0% | 18.9% | On track |
| Revenue | $986M | $2.08B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 32.8% | 38.0% | At risk |
| Customer retention | 85.3% | 93.7% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $275M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the HPV Reagent Market conversation — a $7.11B market you can size, segment and defend in minutes.
Market size · 2033$7.11Btotal opportunity
Growth4.1%CAGR to 2033
Addressable buyers1,632+accounts in scope
Typical ROI7.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.3×return on cost, year one
< 2 mopayback period
$43K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Roche DiagnosticsQiagenHologic Inc.Abbott LaboratoriesBectonDickinson and Company (BD)Thermo Fisher ScientificPerkinElmer Inc.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your HPV Reagent Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
HPV Reagent Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Female Hypoactive Sexual Desire Disorder Therapeutics Market
Market size, share, segmentation and regional forecast.
$854M market · 2025 base year
View reportBeta Catenin Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportErythropoietin Drugs Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportGlycogen Synthase Kinase 3 Beta Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportCritical Limb Ischemia Drug Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportAdrenocorticotropic Hormone Receptor Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportLiver Disease Treatment Market
Market size, share, segmentation and regional forecast.
$376M market · 2025 base year
View reportPlaque Disclosing Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportMarburgvirus Infection Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportAxial Spondyloarthritis Drugs Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportGlutaraldehyde (Pharm Grade) Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportBotulinum Toxin Injection Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.